Move to topTop
April 03, 2017

TOKYO, JAPAN - April 3, 2017 - Terumo Corporation (TSE: 4543) today announced that it completed its acquisition of Bolton Medical, Inc. for US$ 174 million on March 31, 2017 (North American Eastern Standard Time). Bolton Medical is a leading innovator in thoracic and abdominal stent graft systems.

Bolton Medical has become a part of Terumo's Vascular Graft Division within the Cardiac and Vascular Company. The acquisition will enhance Terumo's existing product portfolio in the global stent graft market and our vascular graft business will be further strengthened in the US, in what is the largest stent graft market today.

The impact of the acquisition on Terumo's business performance is being examined. Further details regarding the impact will be disclosed, as needed, once the analysis is completed.

About Bolton Medical, Inc.

Bolton Medical is a leading provider of endovascular solutions for aortic disease based in Sunrise, Florida, US, with 45 million Euros in sales and over 300 employees; committed to improving quality and safety in patient care by developing, manufacturing and distributing innovative, high quality products and technology solely focused on the aorta to include TAA, AAA and custom made stent graft systems.

About Vascular Graft Division of Terumo Corporation

Vascular Graft Division is a division of the Cardiac and Vascular Company, Terumo Corporation. Vascutek Ltd, which became a part of Terumo in 2002, leads this division and has applied advanced and innovative technologies to develop a wide portfolio of products which include an extensive range of sealed woven and knitted polyester grafts for peripheral, abdominal and cardiothoracic surgery. Net sales are 13.9 billion yen (FY2015).

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.